HR Execs on the Move

AdhereTech

www.adheretech.com

 
Smart devices and digital support that connect patients to care, with clinically-proven results https://t.co/zoMxznOfwA
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Gregory Gallo
Chief Revenue Officer (CRO) Profile
Amanda Schumer
Director of People Operations Profile

Similar Companies

West Virginia Primary Care Association

West Virginia Primary Care Association is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Superior Care Home-Nursing

Superior Care Home-Nursing is a Paducah, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Poo~Pourri

Poo~Pourri.com is the home of "Girls Dont Poop!" Shop here to buy gifts, get exclusive offers and awesome other sh*t.

Afferent Pharmaceuticals

Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic disorders arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months or even years.